Inactive Instrument

Tricida, Inc.

Equities

TCDA

US89610F1012

Biotechnology & Medical Research

Tricida, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 11, 2022 at 01:54 am IST

Tricida, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 29.64 million compared to USD 53.36 million a year ago. Basic loss per share from continuing operations was USD 0.51 compared to USD 1.06 a year ago. Diluted loss per share from continuing operations was USD 0.51 compared to USD 1.06 a year ago.

Latest news about Tricida, Inc.

Tricida, Inc. Went Out of Business	12/23/12	CI
First Motion for Exclusivity Period Extension Approved For Tricida, Inc.	01/23/01	CI
Fifth Amended Liquidation Plan Approved for Tricida, Inc.	23/23/23	CI
Fifth Amended Liquidation Plan Filed by Tricida, Inc.	22/23/22	CI
Fourth Amended Liquidation Plan Filed by Tricida, Inc.	12/23/12	CI
First Motion for Exclusivity Period Extension Filed by Tricida, Inc.	08/23/08	CI
North American Morning Briefing : China Data Helps -3-	18/23/18	DJ
North American Morning Briefing : Stock Futures -3-	11/23/11	DJ
Fourth Amended Disclosure Statement Approved for Tricida, Inc.	27/23/27	CI
Fourth Amended Disclosure Statement Filed by Tricida, Inc.	24/23/24	CI
Third Amended Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.	21/23/21	CI
Second Amended Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.	26/23/26	CI
First Amended Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.	24/23/24	CI
Motion for Asset Sale Approved for Tricida, Inc.	22/23/22	CI
Motion for Asset Sale Approved for Tricida, Inc.	22/23/22	CI
Notice of Selection of Successful Bidder Filed for Tricida, Inc.	16/23/16	CI
Notice of Selection of Successful Bidder Filed for Tricida, Inc.	16/23/16	CI
Tricida, Inc. Announces Resignation of David Bonita as Director	28/23/28	CI
Bidding Procedure Approved for Tricida, Inc.	26/23/26	CI
Tricida, Inc.(OTCPK:TCDA.Q) dropped from NASDAQ Composite Index	23/23/23	CI
Top Premarket Gainers	18/23/18	MT
Tricida, Inc.(NasdaqGS:TCDA) dropped from S&P TMI Index	18/23/18	CI
Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.	18/23/18	CI
Tricida, Inc. Filed for Bankruptcy	11/23/11	CI
Motion for Asset Sale Filed by Tricida, Inc.	11/23/11	CI

Chart Tricida, Inc.

Duration

Period

More charts

Company Profile

Tricida, Inc. is a pharmaceutical company. The Company is focused on its investigational drug candidate, veverimer (TRC101). TRC101 is a non-absorbed, orally administered polymer designed to treat metabolic acidosis and slow CKD progression by binding and removing acid from the gastrointestinal (GI) tract. Its veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. Veverimer is a single, high molecular weight, crosslinked polyamine molecule. The size of veverimer prevents systemic absorption from the GI tract. The high degree of cross-linking within veverimer limits swelling and the overall volume in the GI tract, with the goal of facilitating GI tolerability. It is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+45.66%	40.65B
CELLTRION, INC.	-10.72%	27.12B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research